“…To effectively evade CRISPR systems, bacteriophages have evolved protein-based inhibitors, called anti-CRISPRs (Acrs), to inactivate the CRISPR-Cas immune systems (Koonin and Makarova, 2018;Marino et al, 2020;Pawluk et al, 2018). Studies have identified a large number of Acrs, targeting type I (Bondy- Denomy et al, 2013;He et al, 2018;Marino et al, 2018;Pawluk et al, 2014Pawluk et al, , 2016b, type II (Gussow et al, 2020;Eitzinger et al, 2020;Forsberg et al, 2019;Harrington et al, 2017;Hynes et al, 2017Hynes et al, , 2018Lee et al, 2018;Liu et al, 2019;Mahendra et al, 2020;Pawluk et al, 2016a;Rauch et al, 2017;Uribe et al, 2019;Watters et al, 2020), type III (Athukoralage et al, 2020;Bhoobalan-Chitty et al, 2019), type V (Marino et al, 2018;Watters et al, 2018), and recently type VI (Lin et al, 2020) CRISPR-Cas systems. For the type I CRISPR systems, 14 Acrs were described to target the type I-F system (i.e., AcrIF1-IF14), 7 Acrs were found to exclusively target the type I-E system (i.e., AcrIE1-IE7), 1 Acr targeted type I-C (i.e., AcrIC1), and 1 Acr targeted type I-D (i.e., AcrID1) (Hwang and Maxwell, 2019).…”